The relevance of the use of psychotropic drugs in clinical oncology


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

A review of the main foreign studies and recommendations that substantiated the formation of psycho-oncology, a new sub-specialty at the junction of oncology and psychiatry, is presented. Psychiatric disorders in oncological patients are much more common than in the general population, which is associated with the development of adjustment disorders and depression. Even comorbidity of schizophrenia and schizophrenic spectrum disorders in patients with oncological diseases is about 3-4%, and psychiatric symptoms at different stages of treatment are observed in at least 30% of patients. The administration of psychotropic drugs also plays an important role in the provision of palliative care. Specific features of onco-psychiatry include the diagnosis of mental disorders in patients with severe somatic pathology, differential diagnosis of clinically similar symptoms and side effects of antitumor and psychiatric treatment, consideration of potential interactions of drugs used in psychiatry and oncology, determination of the applicability of psychopharmacological preparations for non-psychiatric indications.

Full Text

Restricted Access

About the authors

Yuliya N. Zubkova

N.N. Blokhin National Medical Research Center of Oncology

Email: Москва. Россия;e-mail: kostenay@mail.ru
Psychiatrist, Department of Functional Diagnostics, Intensive Care and Rehabilitation

I. A Kurmukov

N.N. Blokhin National Medical Research Center of Oncology

Department of Functional Diagnostics, Intensive Care and Rehabilitation

O. A Obukhova

N.N. Blokhin National Medical Research Center of Oncology

Department of Functional Diagnostics, Intensive Care and Rehabilitation

Sh. R Kashia

N.N. Blokhin National Medical Research Center of Oncology

Department of Functional Diagnostics, Intensive Care and Rehabilitation

References

  1. Henry G.W. Some modern aspects of psychiatry in general hospital practice. Am. J. Psychiatry 1929;86:481-99
  2. Lipowski Z.J. Consultation-liaison psychiatry at century's end. Psychosomatics. 1992;33:128-33. doi: 10.1176/ajp.131.6.623
  3. Patterson K.R. Psycho-Oncology. In: Psychosomatic medicine. K.D. Ackerman, A.F. DiMartini (ed.). Oxford; New York: Oxford University Press, 2015
  4. Смулевич А.Б. Психосоматические расстройства в онкологии. Эффективная фармакотерапия. 2009;18:28-9. [Smulevich A.B. Psychosomatic disorders in oncology Effektivnaya farmakoterapiya. 2009;18:28-9. (In Russ.)].
  5. Sutherland A.M. Psychological impact of cancer and its therapy. Med. Clin. North Am. 1956;40(3):705-20.
  6. Plumb M., Holland J. Comparative studies of psychological function in patients with advanced cancer -I Self-reported depressive symptoms. Psychosom. Med. 1977;39:264-76.
  7. Maguire G.P., Lee E.G., Bevington D.J., et. al. Psychiatric problems in the first year after mastectomy. Br. Med. J. 1978;15(1):963-65.
  8. Plumb M., Holland J. Comparative studies of psychological function in patients with advanced cancer II. Interviewer-rated current and past psychological symptoms. Psychosom. Med. 1981;43:243-54.
  9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM-III). Washington, D.C.: American Psychiatric Publishing, 1980. 494 p.
  10. Derogatis L.R., Morrow G.R., Fetting J., et al. The prevalence of psychiatric disorders among cancer patient. JAMA. 1983;249(6):751-57.
  11. Hardman A., Maguire P., Crowther D. The recognition of psychiatric morbidity on a medical oncology ward. J. Psychosom. Res. 1989;33:235-39.
  12. Razavi D., Delvaux N., Farvacques C., Robaye E. Screening for adjustment disorders and major depressive disorders in cancer in-patients. Br. J. Psychiatry. 1990;156:79-83.
  13. Grassi L., Rosti G., Lasalvia A., Marangolo M. Psychosocial variables associated with mental adjustment to cancer. Psycho-Oncology. 1993;2:11-20.
  14. Grassi L., Gritti P., Rigatelli M., Gala C. Psychosocial problems secondary to cancer: an Italian multicenter survey of consultation-liason psychiatry in oncology. Eur. J. Cancer. 2000;36:579-85.
  15. Kissane D.W., Grabsch B., Love A., et al. Psychiatric disorder in women with early stage and advanced breast cancer: a comparative analysis. Aust. N. Z. J. Psychiatry. 2004;38:320-6. PMID: 9734576.
  16. Prieto J.M., Blanch J., Atala J., et al. C. Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation. J. Clin. Oncol. 2002;20:1907-17.
  17. Singer S., Szalai C., Briest S., et al. Co-morbid mental health conditions in cancer patients at working age - prevalence, risk profiles, and care uptake. Psychooncology. 2013;22(10):2291-97. doi: 10.1002/pon.3282.
  18. Singer S., Das- Munshi J., Brachler E. Prevalence of mental health conditions in cancer patients in acute care-a meta-analysis. Ann. Oncol. 2010;21:925 30. doi: 10.1093/annonc/mdp515
  19. Mitchell A.J., Chan M., Bhatti H., et al. Prevalence of depression, anxiety, and adjustment disorders in oncological, hematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet. Oncol. 2011;12:160-74.
  20. Miovic M., Block S. Psychiatric disorders in advanced cancer. Cancer. 2007;110:1665-76. doi: 10.1002/cncr.22980.
  21. Смулевич А.Б., Андрющенко А.В., Бескова Д.А. Психические расстройства в онкологии (результаты мультицентровой программы «Синтез»). Психические расстройства в общей медицине. 2009;1:4-12.
  22. Derogatis L.R., Feldstein M., Morrow G., et al. A survey of psychotropic drug prescriptions in an oncology population. Cancer. 1979;44:1919-29.
  23. Jaeger H., Morrow G.R., Carpenter P.J., Brescia F. A survey of psychotropic drug utilization by patients with advanced neoplastic disease. Gen Hosp. Psyciatry. 1985;7:353-60.
  24. Stiefel F.C., Kornblith A.B., Holland J.C. Changes in the prescription patterns of psychotropic drugs for cancer patients during a 10-year period. Cancer. 1990;65:1048-53.
  25. Thekdi S.M., Irarrazaval M.E., Dunn L. Psychopharmacological interventions. In: Grassi L., Riba M., editors. Clinical psycho-oncology:an international perspective. Chichester: Wiley, 2012. P. 109-26.
  26. Caruso R., Grassi L., Nanni M.G., Riba M. Psychopharmacology in psycho-oncology. Curr. Psychiatry Rep. 2013;15(9):393. Doi:10.1007/ s11920-013-0393-0.
  27. Farriols C., Ferrandez O., Planas J., et al. Changes in the prescription of psychotropic drugs in the palliative care of advanced cancer patients over a seven-year period. J. Pain Sympton. Manage. 2012;43:945-52. Doi: 10.1016/j. jpainsymman.2011.05.010.
  28. Desplenter F., Bond C., Watson M., et al. Incidence and drug treatment of emotional distress after cancer diagnosis: a matched primary care case-control study. Br. J. Cancer. 2012;107:1644-51. doi: 10.1038/bjc.2012.364.
  29. De Bock G.H., Musters R.F., Bos H.J., et al. Psychotropoc medication during endocrine treatment for breast cancer. Support Care Cancer. 2012;20:1533-40. doi: 10.1007/s00520-011- 1242-5.
  30. Ng C.G., Boks M.P., Smeets H.M., et al. Prescription patterns for psychotripic drugs in cancer patients; a large population study in the Netherlands. Psychology. 2013;22:762-67. Doi: 10.1002/ pon.3056.
  31. Lindqvist O., Lundquist G., Dickman A., et al. Four essential drugs needed for quality care of the dying: a Delphi-study based international expert consensus opinion. J. Palliative Med. 2013;16:38 43. doi: 10.1089/jpm.2012.0205
  32. Deyell R.J., Lorenzi M., Ma S., et al. Antidepressant use among survives of childhood, adolescent and young adult cancer: a report of the Childhood, Adolescent and Young Adult Cancer Survivor (CAYACS) Research Program. Pediatr. Blood Canc. 2013;60:816-22.
  33. Breitbart W., Alici Y. Evidence-based treatment of delirium in patients with cancer. J. Clin. Oncol. 2012;30:1206-14. Doi:10.1200/ JCO.2011.39.8784.
  34. Rodin G., Lloyd N., Katz M., et al. The treatment of depression in cancer patients: a systematic review. Support Care Cancer. 2007;15(2):123-36.
  35. Okamura M., Akizuki N., Nakano T., et al. Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer. Psychology. 2008;17(2):154-60.
  36. Rayner L., Price A., Evans A., et al. Antidepressants for treatment of depression in palliative care: systematic review and metaanalysis. Palliat. Med. 2011;25(1):36-51. doi: 10.1177/0269216310380764.
  37. Rayner L., Price A., Hotopf M., Higginson I.J. The development of evidence-based European guidelines on the management of depression in palliative cancer care. Eur. J. Cancer. 2011;47(5):702-12. Doi:10.1016/j. ejca.2010.11.027.
  38. Cowan J.D., Palmer T.W. Practical guide to palliative sedation. Curr. Oncol. Rep. 2002;4(3):242-49.
  39. Kehl K.A. Treatment of terminal restlessness: a review of the evidence. J. Pain Palliative Care Pharmacother. 2004;18(1):5-30.
  40. Grassi L., Caruso R., Hammelef K., et al. Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: a review. Int. Rev. Psychiatry 2014;26(1):44-62. doi: 10.3109/09540261.2013.842542.
  41. Ouwens M., Hulscher M., Hermens R., et al. Implementation of integrated care for patients with cancer: a systematic review of interventions and effects. Int. J. Qual Health Care. 2009;21(2):137 44. doi: 10.1093/intqhc/mzn061
  42. Ripamonti C., Santini D., Maranzano E., et al. Management of cancer pain: ESMO clinical practice guidelines. Ann. Oncol. 2012;23(7):139-54.
  43. Bennett M.I. Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review. Palliat. Med. 2011;25:553. doi: 10.1177/0269216310378546.
  44. Bordeleau L., Pritchard K., Goodwin P., Loprinzi C. Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-basedreview. Clin. Therapeut. J. 2007;29(2):230-41. doi: 10.1016/j.clinthera.2007.02.006.
  45. Kast R.E., Foley K. Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur. J. Cancer Care (Engl). 2007;16:351-54. doi: 10.1111/j.1365-2354.2006.00760.x.
  46. Riechelmann R.P., Burman D., Tannock I.F., et al. Phase II trial of mirtazapine for cancer-related cachexia and anorexia. Am. J. Hosp. Pallat. Care. 2012;27:106-10. doi: 10.1177/1049909109345685.
  47. Breitbart W., Alici-Evcimen Y. Update on psychotropic medications for cancer-related fatigue. J. Natl. Compr. Canc. Netw. 2007;5:1081-91.
  48. Minton O., Richardson A., Sharpe M., et al. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J. Natl. Cancer Inst. 2008;100:1155-66. doi: 10.1093/jnci/djn250.
  49. Breitbart W., Alici Y. Psychostimulants for cancer-related fatigue. J. Natl. Compr. Canc. Netw. 2010;8:933-42.
  50. Minton O., Richardson A., Sharpe M., et al. Psychostimulants for the management of cancer-related fatigue: a systematic review and metaanalysis. J. Pain Symptom Manage. 2011;41:761-67. doi: 10.1016/j.jpainsymman.2010.06.020.
  51. Bennett M.I., Laird B., Van Litsenburg C., Nimour M. Pregabalin for management of neuropathic pain in adults with cancer: a systematic review of the literature. Pain Med. 2013;5:132-36. doi: 10.1111/pme.12212.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies